Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Net Margin (2020 - 2026)

Insight Molecular Diagnostics' Net Margin history spans 6 years, with the latest figure at 2015.36% for Q4 2025.

  • On a quarterly basis, Net Margin rose 23975.0% to 2015.36% in Q4 2025 year-over-year; TTM through Dec 2025 was 1238.52%, a 200050.0% increase, with the full-year FY2025 number at 1238.52%, up 200050.0% from a year prior.
  • Net Margin hit 2015.36% in Q4 2025 for Insight Molecular Diagnostics, up from 4174.62% in the prior quarter.
  • Over the last five years, Net Margin for IMDX hit a ceiling of 1.65% in Q1 2023 and a floor of 16497.81% in Q4 2022.
  • Historically, Net Margin has averaged 4005.51% across 5 years, with a median of 2135.24% in 2024.
  • Biggest five-year swings in Net Margin: soared 6166383bps in 2021 and later tumbled -1549795bps in 2022.
  • Tracing IMDX's Net Margin over 5 years: stood at 999.86% in 2021, then tumbled by -1550bps to 16497.81% in 2022, then soared by 74bps to 4225.8% in 2023, then surged by 47bps to 2255.11% in 2024, then rose by 11bps to 2015.36% in 2025.
  • Business Quant data shows Net Margin for IMDX at 2015.36% in Q4 2025, 4174.62% in Q3 2025, and 1880.69% in Q2 2025.